Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages
Metrics: PDF 3493 views | HTML 2732 views | ?
Ling Ding1, Guikai Liang1, Zhangting Yao1, Jieqiong Zhang1, Ruiyang Liu1, Huihui Chen1, Yulu Zhou1, Honghai Wu1, Bo Yang1, Qiaojun He1
1Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
Qiaojun He, e-mail: email@example.com
Keywords: metformin, macrophage polarization, cancer metastasis, AMPKα1
Received: July 05, 2015 Accepted: October 09, 2015 Published: October 19, 2015
Accumulated evidence suggests that M2-like polarized tumor associated macrophages (TAMs) plays an important role in cancer progression and metastasis, establishing TAMs, especially M2-like TAMs as an appealing target for therapy intervention. Here we found that metformin significantly suppressed IL-13 induced M2-like polarization of macrophages, as illustrated by reduced expression of CD206, down-regulation of M2 marker mRNAs, and inhibition of M2-like macrophages promoted migration of cancer cells and endothelial cells. Metformin triggered AMPKα1 activation in macrophage and silencing of AMPKα1 partially abrogated the inhibitory effect of metformin in IL-13 induced M2-like polarization. Administration of AICAR, another activator of AMPK, also blocked the M2-like polarization of macrophages. Metformin greatly reduced the number of metastases of Lewis lung cancer without affecting tumor growth. In tumor tissues, the percentage of M2-like macrophage was decreased and the area of pericyte-coated vessels was increased. Further, the anti-metastatic effect of metformin was abolished when the animals were treated with macrophages eliminating agent clodronate liposome. These findings suggest that metformin is able to block the M2-like polarization of macrophages partially through AMPKα1, which plays an important role in metformin inhibited metastasis of Lewis lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.